



Metrion Biosciences appoints Nick Foster as Chief Commercial Officer and Head of Global Business Development

Appointment supports international growth within ion channel contract research and drug discovery

Cambridge, UK, 26 July 2021: Metrion Biosciences Limited ("Metrion"), the specialist ion channel contract research and drug discovery company, today announced the appointment of Nick Foster as Chief Commercial Officer and Head of Global Business Development, to support the broadening of Metrion's international customer base and facilitate entry into new territories. The appointment follows the recently announced £2.7m new equity investment led by Gresham House Ventures and forms part of the Company's significant growth strategy for 2021 and 2022, with a focus on the USA, EU and Japan.



Nick has a strong technical background in protein engineering and drug metabolism studies, as well as global business development and marketing expertise, and an understanding of the early drug discovery and safety profiling process and the importance of customer relationships. Following his early career as a laboratory scientist, Nick moved into business development, holding positions as Associate Director, Business Development Europe for BioFocus Limited (now Charles River Laboratories), Head of Commercial Operations at Optibrium Limited, and Director, Business Development for WuXi AppTec. Nick has an undergraduate degree in Applied Biochemistry from Liverpool John Moores University, UK.

Dr Andrew Southan, Chief Executive Officer of Metrion Biosciences, said: "I am very pleased to welcome Nick to Metrion's senior management team. His background and experience will be crucial to the next phase of Metrion's growth and I look forward to working with him to achieve our corporate objectives."

Nick Foster Chief Commercial Officer, Metrion Biosciences, commented: "I am delighted to be joining Metrion at this exciting time of expansion for the company. Metrion has established itself as a global leader in ion channel drug discovery and I look forward to working with the team to support these services, engage with our collaborators and develop new opportunities to further expand our global partnerships."

-ENDS-

Notes to Editors

	
Andy Southan, Chief Executive Officer, Metrion Biosciences	Nick Foster, Chief Commercial Officer, Metrion Biosciences

For high resolution images please contact Zyme Communications

Media contact:

Katie Odgaard

Zyme Communications

E-mail: katie.odgaard@zymecommunications.com

Tel: +44 (0)7787 502 947

To opt-out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy, please [click here](#).

About Metrion Biosciences

Metrion Biosciences is a specialist ion-channel contract research organization and drug discovery business. The Company provides customers with access to a range of high-quality ion channel assays on a fee-for-service or collaboration basis. Metrion Biosciences' ion channel expertise includes an industry leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Metrion Biosciences is able to provide tailored assay formats, data analysis and reporting solutions, effective project management and quality assured data packages.

For more information, please visit www.metrionbiosciences.com

LinkedIn: [@metrion-biosciences](#) | Twitter: [@metrion_biosci](#)